21278-85-3

Usage

Heterocyclic compound

Yes, it contains both nitrogen and sulfur atoms in its ring structure.

Ethyl ester derivative

Yes, it is derived from 2-(4-pyridinyl)-4-thiazolecarboxylic acid by attaching an ethoxy group to the carboxyl group.

Potential pharmaceutical applications

Yes, it has been studied for its potential as an antimicrobial and antifungal agent.

Potential as a precursor for the synthesis of other biologically active compounds

Yes, it can be used as a building block in the synthesis of other organic molecules.

Potential use as a ligand in coordination chemistry

Yes, it has been investigated for its ability to bind to metal ions.

Versatile compound

Yes, it has potential applications in medicinal chemistry, pharmaceuticals, and materials science.

Upstream product

• 15933-07-0 Ethyl 2-oxobutanoate 
• 2196-13-6 pyridine-4-carbothioamide 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 21278-86-4 2-(4-Pyridyl)-1,3-thiazole-4-carboxylic acid 
• 321429-91-8 N-(3''-dimethylaminopropyl)-2-(pyridin-4'-yl)thiazole-4-carboxamide 
• 533885-37-9 2-(4-pyridinyl)-1,3-thiazole-4-carbaldehyde 
• 21278-93-3 2-pyridin-4-yl-thiazole-4-carboxylic acid N'-(toluene-4-sulfonyl)-hydrazide 
• 21278-90-0 2-pyridin-4-yl-thiazole-4-carboxylic acid (4-nitro-benzylidene)-hydrazide 
• 21278-91-1 2-pyridin-4-yl-thiazole-4-carboxylic acid (4-hydroxy-3-methoxy-benzylidene)-hydrazide 
• 21278-92-2 2-pyridin-4-yl-thiazole-4-carboxylic acid [1-(4-amino-phenyl)-ethylidene]-hydrazide 
• 21278-89-7 1-Furfuryliden-2-<2-(pyridyl-4)-thiazolyl-4-carbonyl>-hydrazin 

Relevant academic research and scientific papers

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.